Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Reuters

08/20

<a href="https://laohu8.com/S/TIVC">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers

Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560105142"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560105142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560105142?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560105142","market":"us","top_or_hot":-1,"title":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-20 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> applications for their lead candidate, Entolimod™, from <a href=\"https://laohu8.com/S/STAB\">Statera Biopharma</a>. These INDs are aimed at the treatment of acute radiation syndrome <a href=\"https://laohu8.com/S/ARS.UK\">$(ARS.UK)$</a> and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIVC","symbol_name":"Tivic Health Systems, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL4HZTRK:1","article_id":"2560105142","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560105142","pubTimestamp":1755693066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod to Treat Acute Radiation Syndrome and Advanced Cancers. Tivic Health Systems Inc. has announced the receipt of two investigational new drug  applications for their lead candidate, Entolimod, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome  and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIVC":"Tivic Health Systems, Inc.","BK4139":"生物科技","BK4082":"医疗保健设备","STAB":"Statera Biopharma Inc"},"translate_title":"Tivic Health获得FDA批准两项恩托莫德研究性新药申请™治疗急性放射综合征和晚期癌症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAB":0.9,"TIVC":0.9},"content_text":"Tivic Health Receives FDA Approval for Two Investigational New Drug Applications for Entolimod™ to Treat Acute Radiation Syndrome and Advanced Cancers\n    \n\n        Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820053049) on August 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}